These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32772054)

  • 1. The use of buprenorphine in the treatment of drug-resistant depression - an overview of the studies.
    Stefanowski B; Antosik-Wójcińska A; Święcicki Ł
    Psychiatr Pol; 2020 Apr; 54(2):199-207. PubMed ID: 32772054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of opioid modulation in major depressive disorder.
    Ehrich E; Turncliff R; Du Y; Leigh-Pemberton R; Fernandez E; Jones R; Fava M
    Neuropsychopharmacology; 2015 May; 40(6):1448-55. PubMed ID: 25518754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder.
    Ragguett RM; Rong C; Rosenblat JD; Ho RC; McIntyre RS
    Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):475-482. PubMed ID: 29621905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine: prospective novel therapy for depression and PTSD.
    Madison CA; Eitan S
    Psychol Med; 2020 Apr; 50(6):881-893. PubMed ID: 32204739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial.
    Fava M; Memisoglu A; Thase ME; Bodkin JA; Trivedi MH; de Somer M; Du Y; Leigh-Pemberton R; DiPetrillo L; Silverman B; Ehrich E
    Am J Psychiatry; 2016 May; 173(5):499-508. PubMed ID: 26869247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Buprenorphine in treatment of refractory depression-A review of current literature.
    Stanciu CN; Glass OM; Penders TM
    Asian J Psychiatr; 2017 Apr; 26():94-98. PubMed ID: 28483102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review.
    Serafini G; Adavastro G; Canepa G; De Berardis D; Valchera A; Pompili M; Nasrallah H; Amore M
    Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30111745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful Treatment of Major Depressive Disorder With Add-On Buprenorphine in a Patient With Previous Nonresponse to Standard Antidepressants.
    Elsayed M; Gahr M; Connemann BJ; Schönfeldt-Lecuona C
    Prim Care Companion CNS Disord; 2017 Sep; 19(5):. PubMed ID: 28972704
    [No Abstract]   [Full Text] [Related]  

  • 9. A meta-analysis of the potential antidepressant effects of buprenorphine versus placebo as an adjunctive pharmacotherapy for treatment-resistant depression.
    Dinoff A; Lynch ST; Sekhri N; Klepacz L
    J Affect Disord; 2020 Jun; 271():91-99. PubMed ID: 32479336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abuse Potential of Buprenorphine/Samidorphan Combination Compared to Buprenorphine and Placebo: A Phase 1 Randomized Controlled Trial.
    Pathak S; Vince B; Kelsh D; Shram MJ; Setnik B; Lu H; Nangia N; Stanford AD; Ehrich E
    J Clin Pharmacol; 2019 Feb; 59(2):206-217. PubMed ID: 30102427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies.
    Fava M; Thase ME; Trivedi MH; Ehrich E; Martin WF; Memisoglu A; Nangia N; Stanford AD; Yu M; Pathak S
    Mol Psychiatry; 2020 Jul; 25(7):1580-1591. PubMed ID: 30374191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic administration of buprenorphine in combination with samidorphan produces sustained effects in olfactory bulbectomised rats and Wistar-Kyoto rats.
    Burke NN; Li Y; Deaver DR; Finn DP; Roche M; Eyerman DJ; Sanchez C; Kelly JP
    J Psychopharmacol; 2019 Dec; 33(12):1620-1627. PubMed ID: 31512988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ketamine's rapid antisuicidal effects are not attenuated by Buprenorphine.
    Hosanagar A; Schmale A; LeBlanc A
    J Affect Disord; 2021 Mar; 282():252-254. PubMed ID: 33418374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipanic-like effect of esketamine and buprenorphine in rats exposed to acute hypoxia.
    Maraschin JC; Frias AT; Hernandes PM; Batistela MF; Martinez LM; Joca SRL; Graeff FG; Audi EA; Spera de Andrade TGC; Zangrossi H
    Behav Brain Res; 2022 Feb; 418():113651. PubMed ID: 34732354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent Use of Buprenorphine, Methadone, or Naltrexone Does Not Inhibit Ketamine's Antidepressant Activity.
    Marton T; Barnes DE; Wallace A; Woolley JD
    Biol Psychiatry; 2019 Jun; 85(12):e75-e76. PubMed ID: 30926131
    [No Abstract]   [Full Text] [Related]  

  • 16. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Individual and Societal Burden of Treatment-Resistant Depression: An Overview.
    Baig-Ward KM; Jha MK; Trivedi MH
    Psychiatr Clin North Am; 2023 Jun; 46(2):211-226. PubMed ID: 37149341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults.
    Karp JF; Butters MA; Begley AE; Miller MD; Lenze EJ; Blumberger DM; Mulsant BH; Reynolds CF
    J Clin Psychiatry; 2014 Aug; 75(8):e785-93. PubMed ID: 25191915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What are the comparative benefits and harms of augmentation treatments in major depression?
    Shelton RC
    J Clin Psychiatry; 2015 Apr; 76(4):e531-3. PubMed ID: 25919851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression.
    Lin C; Karim HT; Pecina M; Aizenstein HJ; Lenze EJ; Blumberger DM; Mulsant BH; Kharasch ED; Reynolds Iii CF; Karp JF
    Neuroimage Clin; 2019; 21():101679. PubMed ID: 30685701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.